Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Feb 17, 2025
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding NEMLUVIO (EC Approval for the Treatment of Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis)
TOKYO, February 17, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on February 14 that they have received approval from the European Commission for NEMLUVIO® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. Nemolizumab was created by Chugai, and its clinical development and marketing outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularishttps://www.galderma.com/news/galdermas-nemluvior-nemolizumab-approved-european-union-moderate-severe-atopic-dermatitis-and
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp